Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The $3.6 billion antitrust court case cleared Gilead Sciences and Teva of delaying the release of generic Truvada and other HIV meds.
An HIV prevention roundup
At the center of the lawsuit is Teva Pharmaceutical, slated to sell a generic version of the HIV prevention pill PrEP next year.
Only one company will sell a version of the HIV prevention pill Truvada. When others go to market, prices will likely drop further.
Pharma sets the prices for HIV and hep C drugs very high. What happens to those prices along the supply chain?
The tablet from the South Korean company Celltrion contains tenofovir disoproxil fumarate and lamivudine.
This marks the manufacturer’s fifth generic antiretroviral launch.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.